Oculis Holding

OCS

Market cap $647M

Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis' management will participate in a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Conference.

LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or "the Company") (NASDAQ: OCS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Oculis Holding AG shares collapsed approximately 23% after Phase 3 DIAMOND trials for lead product OCS-01 failed to meet the primary endpoint in diabetic macular edema. NEW YORK, June 8, 2026 /PRNewswire/ -- Investors in Oculis Holding AG (NASDAQ: OCS) lost approximately 23% of their share value in a single session after the company disclosed that its Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 eye drops failed to meet the primary endpoint in diabetic macular edema (DME) -- and that Oculis would not pursue an FDA filing for the indication.

Nan Fung Group Holdings sold 163,957 Oculis (OCS) shares in Q1 2026, with an estimated transaction value of $4.3 million. After the sale, Nan Fung's remaining stake of 350,745 shares was valued at approximately $9.3 million -- representing 7.7% of the fund's assets under management (AUM) -- making Oculis the fourth-largest position in the portfolio.

New York, New York--(Newsfile Corp. - June 8, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Oculis Holding AG ("Oculis Holding AG") (NASDAQ: OCS) concerning potential violations of the federal securities laws. Multiple SEC filings made prior to the stock collapse continued to present the OCS-01 DME program as progressing toward regulatory approval.

LOS ANGELES--(BUSINESS WIRE)---- $OCS--OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm.

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or the "Company") (NASDAQ: OCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Shareholders who held Oculis Holding AG (NASDAQ: OCS) stock lost more than 23% of their investment in a single session after the company disclosed that Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 failed to meet the primary endpoint in diabetic macular edema -- and that it would not pursue an FDA filing for the indication. Those who suffered losses on OCS are encouraged to submit their information to discuss their legal rights.

NEW YORK--(BUSINESS WIRE)--Shareholders of Oculis Holding AG (NASDAQ: OCS) lost nearly $7 per share, more than 23%, in a single trading session when the company disclosed that its Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 failed to meet the primary endpoint -- mean change in best-corrected visual acuity at week 52 -- in diabetic macular edema. Oculis simultaneously announced it would not pursue an FDA filing for the DME indication. Investors who lost money on OCS are encouraged to submi.

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG (“Oculis” or the “Company”) (NASDAQ: OCS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.